Regorafenib in Indian Patients With Metastatic Colorectal Cancer (mCRC).

Summary

This is a Phase IV, single-arm, prospective, open-label, multicenter, interventional study to evaluate safety and efficacy of regorafenib in patients with mCRC who have been previously treated with fluoropyrimidine , oxaliplatin-, and irinotecan based chemotherapy, an anti-VEGF therapy, and, if RAS wild type, an anti-EGFR therapy.

Timeline

Start

2018-07-30

Primary completion

2023-03-20

Completion

2023-12-01

Drugs

Indications